GHRH analogue is one of those subjects where the details matter more than the headlines. This page pulls together the background, the mechanisms, and the practical points readers ask about most.
Updated 2026-02-28. Numbers and descriptions here follow the published literature rather than marketing material.
Tesamorelin is a synthetic peptide built from 44 amino acids and classified with the growth hormone–releasing hormone family. Its sequence corresponds to the human GHRH(1-44) backbone, carrying one structural change at the amino terminus. That change is a trans-3-hexenoyl group placed where the natural peptide would have an unmodified end. The modification is the feature that separates the compound from the endogenous hormone in name, in stability, and in how it is handled in the laboratory.
The hexenoyl cap slows the enzyme step that trims the amino terminus of native GHRH, the same step that shortens its active lifetime in circulation. As a result, the modified peptide persists longer in plasma than the unmodified hormone in side-by-side comparison. Receptor activity stays broadly comparable, because the added group sits away from the residues that contact the binding site. This combination, preserved receptor activity with reduced degradation, explains why the analog was developed instead of the native sequence.
Measuring the effect of a growth hormone-releasing hormone analogue requires markers that reflect pituitary output rather than the peptide itself. The two most frequently used are growth hormone and insulin-like growth factor 1. Growth hormone fluctuates sharply across the day and responds to sleep, stress, and meals, so isolated readings can be difficult to interpret. Insulin-like growth factor 1 changes more slowly and is often treated as the more stable integrated marker of axis activity.
Because growth hormone is released in pulses, single measurements can misrepresent overall secretion. Investigators sometimes use repeated sampling or overnight profiles to capture the pattern rather than a single value. Provocative testing, in which a stimulus is given and the response is tracked over time, offers another way to characterize the axis. Each approach carries trade-offs between sensitivity, burden on the participant, and the influence of non-target variables.
Insulin-like growth factor 1 is produced largely in the liver in response to growth hormone signaling. Its concentration shifts over days rather than minutes, which makes it practical for tracking changes across a study period. Interpretation still depends on age, nutritional status, and concurrent illness, all of which independently affect the marker. Reference ranges are therefore stratified, and comparisons are usually made within an individual over time rather than against a single population threshold.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Synthetic peptide | GHRH analog family |
| Residue count | 44 amino acids | Matches human GHRH(1-44) backbone |
| N-terminal group | trans-3-hexenoyl | Main structural difference from native hormone |
| Appearance | White to off-white powder | Lyophilized solid form |
| Solubility class | Freely soluble in water | Peptide character; less soluble in organic solvents |
A documented effect of tesamorelin is a reduction in visceral adipose tissue in some study populations. Researchers have reported decreases in trunk fat measured by computed tomography alongside changes in lipid markers. The mechanism is thought to involve growth hormone-mediated lipolysis, though the precise contribution of direct versus indirect pathways is not fully resolved. Studies have generally examined defined groups over finite periods, so long-term outcomes are less well characterized. Findings have not been uniform across all trials.
Tesamorelin is a synthetic peptide analog of growth hormone-releasing hormone (GHRH). Its sequence corresponds to the 44-amino-acid form of human GHRH with a trans-3-hexenoyl group attached to the N-terminal tyrosine. This modification slows enzymatic cleavage and extends the peptide's activity relative to the native hormone. The compound is produced by solid-phase peptide synthesis and supplied as a lyophilized powder. Researchers classify it as a GHRH receptor agonist. Its structure places it in the same family as other growth hormone secretagogues that act on the pituitary.
Binding of tesamorelin to GHRH receptors on pituitary somatotroph cells triggers cyclic AMP signaling and the release of growth hormone into circulation. Because the peptide acts upstream of the growth hormone axis, its effects are partly mediated by hepatic insulin-like growth factor 1 (IGF-1) production. The pulsatile character of endogenous growth hormone secretion is preserved rather than replaced. Whether amplified signaling produces effects beyond those of native GHRH remains an area of ongoing investigation.
Stimulated growth hormone release leads to hepatic production of insulin-like growth factor 1, a key mediator of many growth hormone effects. In clinical studies, tesamorelin increased IGF-1 levels in a dose-dependent manner, although the response varies among individuals. The drug's effect on visceral fat is thought to involve growth hormone-mediated lipolysis and altered adipocyte metabolism. Muscle mass and lean body mass have also been assessed as secondary outcomes, but changes are generally smaller and less consistent than fat reductions.
Pharmacodynamic studies show that tesamorelin reduces visceral adipose tissue more than subcutaneous adipose tissue in the studied population. This selectivity may relate to differences in blood flow and hormone sensitivity between fat depots. Effects on glucose metabolism and insulin sensitivity have been investigated, with some trials reporting modest changes and others showing stability. The precise relationship between growth hormone exposure, IGF-1 levels, and visceral fat loss remains an active area of analysis.
Tesamorelin is a synthetic peptide that belongs to the growth hormone-releasing hormone family and contains the same forty-four amino acid sequence as endogenous GHRH, extended at the amino terminus by a trans-3-hexenoyl group. That small fatty acid modification protects the peptide from rapid cleavage by dipeptidyl peptidase-4, the enzyme that shortens the half-life of native GHRH to only a few minutes. Chemically the compound is produced by solid-phase peptide synthesis, purified by chromatography, and supplied as a sterile lyophilized powder for reconstitution.
Regulatory approval in the United States came in 2010, when the Food and Drug Administration cleared the peptide for the reduction of excess abdominal fat in adults with HIV infection and associated lipodystrophy. The decision rested mainly on two randomized phase 3 trials that enrolled roughly eight hundred patients and ran for twenty-six weeks. Participants receiving active drug showed substantially greater declines in visceral adipose tissue than those receiving placebo, while total body weight changed comparatively little. A reformulated presentation was later approved, and the product has remained a niche therapy rather than a general weight-loss agent.
Lyophilized tesamorelin is generally stored refrigerated at temperatures between 2 and 8 degrees Celsius. The solid form is comparatively stable when kept dry and protected from light. Moisture uptake can promote aggregation and degradation, so sealed containers with desiccant are common. Researchers typically avoid repeated temperature cycling, which may stress the peptide. Documentation accompanying reference materials usually specifies a shelf life under these conditions.
Once reconstituted, the peptide is handled as a solution and is less stable than the lyophilized powder. Aqueous solutions are commonly kept cold and used within a defined period. Buffer composition and pH influence degradation rates, with extremes of acidity or alkalinity accelerating hydrolysis. Preservatives may be added in multi-dose formats to limit microbial growth. Freezing and thawing of solutions is generally avoided because it can cause precipitation or loss of activity.
Identity and purity are assessed by reversed-phase high-performance liquid chromatography, which separates the peptide from related impurities. Mass spectrometry, often coupled to liquid chromatography, confirms molecular mass and detects chemical modifications. Peptide mapping and amino acid analysis can verify sequence integrity. Water content is measured by Karl Fischer titration, and residual solvents may be checked by gas chromatography. These methods together support batch-to-batch consistency and routine quality control.
=== Graphene manufacture === Graphite oxide has attracted much interest as a possible route for the large-scale production and manipulation of graphene, a material with extraordinary electronic properties. Graphite oxide itself is an insulator, almost a semiconductor, with differential conductivity between 1 and 5×10−3 S/cm at a bias voltage of 10 V. However, being hydrophilic, graphite oxide disperses readily in water, breaking up into macroscopic flakes, mostly one layer thick. Chemical reduction of these flakes would yield a suspension of graphene flakes. It was argued that the first experimental observation of graphene was reported by Hanns-Peter Boehm in 1962. In this early work the existence of monolayer reduced graphene oxide flakes was demonstrated. The contribution of Boehm was recently acknowledged by Andre Geim, the Nobel Prize winner for graphene research. Partial reduction can be achieved by treating the suspended graphene oxide with hydrazine hydrate at 100 °C for 24 hours, by exposing graphene oxide to hydrogen plasma for a few seconds, or by exposure to a strong pulse of light, such as that of a xenon flash. Due to the oxidation protocol, manifold defects already present in graphene oxide hamper the effectiveness of the reduction. Thus, the graphene quality obtained after reduction is limited by the precursor quality (graphene oxide) and the efficiency of the reducing agent. However, the conductivity of the graphene obtained by this route is below 10 S/cm, and the charge mobility is between 0.1 and 10 cm2/Vs.
If siRNA is able to successfully reach its target, it has the potential to therapeutically regulate gene expression through its ability to base-pair to mRNA targets and promote their degradation through the RISC system Currently, siRNA-based therapy is in a phase I clinical trial for the treatment of age-related macular degeneration, although it is also being explored for use in cancer therapy. For instance, siRNA can be used to target mRNAs that code for proteins that promote tumor growth such as the VEGF receptor and telomerase enzyme.
=== Compound applications === Molybdenum disulfide (MoS2) is used as a solid lubricant and a high-pressure high-temperature (HPHT) anti-wear agent. It forms strong films on metallic surfaces and is a common additive to HPHT greases — in the event of a catastrophic grease failure, a thin layer of molybdenum prevents contact of the lubricated parts. When combined with small amounts of cobalt, MoS2 is also used as a catalyst in the hydrodesulfurization (HDS) of petroleum. In the presence of hydrogen, this catalyst facilitates the removal of nitrogen and especially sulfur from the feedstock, which otherwise would poison downstream catalysts. HDS is one of the largest scale applications of catalysis in industry. Molybdenum oxides are important catalysts for selective oxidation of organic compounds. The production of the commodity chemicals acrylonitrile and formaldehyde relies on MoOx-based catalysts. Molybdenum disilicide (MoSi2) is an electrically conducting ceramic with primary use in heating elements operating at temperatures above 1500 °C in air. Molybdenum trioxide (MoO3) is used as an adhesive between enamels and metals. Lead molybdate (wulfenite) co-precipitated with lead chromate and lead sulfate is a bright-orange pigment used with ceramics and plastics. The molybdenum-based mixed oxides are versatile catalysts in the chemical industry. Some examples are the catalysts for the oxidation of carbon monoxide, propylene to acrolein and acrylic acid, the ammoxidation of propylene to acrylonitrile.
== Macromolecules in nature == Proteins are polymers of amino acids joined by peptide bonds. DNA and RNA are polymers of nucleotides joined by phosphodiester bonds. These nucleotides consist of a phosphate group, a sugar (ribose in the case of RNA, deoxyribose in the case of DNA), and a nucleotide base (either adenine, guanine, thymine, uracil, or cytosine, where thymine occurs only in DNA and uracil only in RNA). Polysaccharides (such as starch, cellulose, and chitin) are polymers of monosaccharides joined by glycosidic bonds. Some lipids (organic nonpolar molecules) are macromolecules, with a variety of different structures.
Sources: en.wikipedia.org
Vegans had a lower dietary intake of vitamin D and lower serum 25(OH)D when compared to omnivores, with lacto-ovo-vegetarians falling in between due to the vitamin content of egg yolks and fortified dairy products. Governments have mandated or voluntary food fortification programs to bridge the difference in, respectively, 15 and 10 countries. The US is one of the few mandated countries. The original fortification practices, circa the early 1930s, were limited to cow's milk, which had a large effect on reducing infant and child rickets. In July 2016 the US Food and Drug Administration approved the addition of vitamin D to plant milk beverages intended as milk alternatives, such as beverages made from soy, almond, coconut, and oats. At an individual level, people may choose to consume a multivitamin/mineral product or else a vitamin-D-only product. There are many disease states, medical treatments, and medications that put people at risk for vitamin D deficiency. Chronic diseases that increase risk include kidney and liver failure, Crohn's disease, inflammatory bowel disease, and malabsorption syndromes such as cystic fibrosis, and hyper- or hypo-parathyroidism. Obesity sequesters vitamin D in fat tissues, thereby lowering serum levels, but bariatric surgery to treat obesity interferes with dietary vitamin D absorption, also causing deficiency. Medications interacting with vitamin D metabolism include antiretrovirals, anti-seizure drugs, glucocorticoids, systemic antifungals such as ketoconazole, cholestyramine, and rifampicin.
During this period, state and local governments initiated controversial drug policies that demonstrated racial biases, such as the stop-and-frisk police practice in New York City, and state-level "three strikes" felony laws, which began with California in 1994. During the 1990s, opioid use in the US dramatically rose, leading to the ongoing situation commonly called the opioid epidemic. A loose consensus of observers describe three main phases to date: overprescription of legal opioids beginning in the early to mid-1990s; a rise in heroin use in the later 2000s as prescription opioids became more difficult to obtain; and the rise of more powerful fentanyl and other synthetic opioids around the mid-2010s. Prior to 1990s, the use of opioids to treat chronic pain in the US was limited; some scholars suggest there was hesitation to prescribe opioids due to historical problems with addiction dating back to the 1800s. A critical point in the development of the epidemic is often seen as the release in 1996 of OxyContin (oxicodone) by Purdue Pharma, and the subsequent aggressive and deceptive opioid marketing efforts by Purdue and other pharma companies, conducted without sufficient official oversight. Thus the problem emerged from within the healthcare system: the DEA initially targeted doctors, pharmacists, pill mills, and pharmaceutical companies. As law enforcement cracked down on the pharmaceutical supply, illicit drug trafficking in opioids grew to meet demand. The George W. Bush (2001–2009) administration maintained the hard line approach.
== History == Physicians historically used odors as a diagnostic indicator to judge a patient's health. Hippocrates saw the breath of patients as a potential indicator in around 400 BCE. Galen, Avicenna, and other physicians considered urine scent alongside color, density, sediments, and more in urinalysis. Urine with a sweet odor was diagnosed as possessing dominating sanguine humor relative to the other three humors; pungent odor as an excessive amount of bile; and foul odor as the presence of ulcers in the urinary tract or development of putrefactive fever, a fever occurring in the humors. VOCs are currently deemed as noninvasive diagnostic biomarkers with the potential for point-of-care (POC) testing and long-term monitoring.
==== The Annona ==== The first indication of a collective, organized food distribution system within the Roman Republic comes from the annona. Originally meaning "yearly return", the annona became the administrative term for governmental bread and grain distribution. Over time, annona came to represent the distribution of all pertinent foods in the Roman diet. The annona was originally organized between 500 and 50 BCE, and gained increasing influence in the centuries to come. The practice of specifically distributing grain to the plebeian class, known as frumentationes, gained prominence around 120 BCE and supplemented the efforts of the annona to feed the Roman people. Emperor Augustus officially changed the annona system between 8 and 14 CE. He established the position of praefectus annonae, Prefect of the Annona. Up to this point in time, the annona was handled by local government officials called aediles. Augustus’ Prefect of the Annona oversaw all transportation, weighing, inspection, and storing of state foods. The physical distribution of foods throughout the Roman Empire varied by location and type of food. Some foods were shipped by boat and then distributed once they reached port. Others, specifically meat, were transported by land and brought into urban areas. Special regulations were put in place for the distribution of olive oil, as the Empire made contracts with olive oil producers all over the Mediterranean. Free daily distributions of olive oil were enacted by Emperor Severus during his reign from 192 to 211 CE.
The military responded with force and in the ensuing crossfire some 120 people lost their lives, including most of the guerrillas (several high-ranking operatives among them) and 12 Supreme Court Judges.[1] Both sides blamed each other for the bloodbath, which marked the end of Betancur's peace process.[2] Meanwhile, individual FARC members initially joined the UP leadership in representation of the guerrilla command, though most of the guerrilla's chiefs and militiamen did not demobilize nor disarm, as that was not a requirement of the process at that point in time. Tension soon significantly increased, as both sides began to accuse each other of not respecting the cease-fire. According to historian Daniel Pecáut, the creation of the Patriotic Union took the guerrillas' political message to a wider public outside of the traditional communist spheres of influence and led to local electoral victories in regions such as Urabá and Antioquia, with their mayoral candidates winning 23 municipalities and their congressional candidates gaining 14 seats (five in the Senate, nine in the lower Chamber) in 1988. Pecáut stated that new recruits entered the guerrilla army and its urban militia units during this period, and that the FARC continued to carry out kidnappings and target regional politicians for assassination.
Sources: en.wikipedia.org
Instead, the company offered to provide the medication free through its patient access program for hardship cases, though this option was described as much more restrictive. Oncologists criticized the decision as unprecedented, with Dr. Carmen de Ramon Ortiz of Geneva University Hospital noting that about 20% of follicular lymphoma patients require intensive treatment and that Lunsumio represents "a very innovative immunotherapy that stimulates the immune system, leading to high remission rates." Industry experts characterized the withdrawal as a form of healthcare rationing and a "canary in the coal mine," noting that only half of EU-approved medications are available in Switzerland. Some experts suggested the withdrawal reflected broader pressures from potential U.S. pricing reforms and trade uncertainties that could affect Roche's largest market, including potential tariff increases on pharmaceutical exports from 10% to up to 31%. The case was viewed by analysts as a potential precedent-setting "regulatory showdown" that could influence pharmaceutical pricing negotiations across the industry, particularly for rare disease treatments affecting small patient populations.
=== Post-translational modification === Additionally, the protein can undergo a variety of post-translational modifications, which are briefly summarized here. The N-terminal amino group of a polypeptide can be modified covalently, e.g.,
Some colorless compounds such as proteins can be quantified at an Optical Density of 280 nm due to the presence of aromatic rings such as tryptophan, tyrosine and phenylalanine but if none of these amino acids are present then the absorption cannot be measured at 280 nm.
=== Brand names === Mianserin is marketed in many countries mainly under the brand name Tolvon. It is also available throughout the world under a variety of other brand names including Athymil, Bonserin, Bolvidon, Deprevon, Lantanon, Lerivon, Lumin, Miansan, Serelan, Tetramide, and Tolvin among others.
Sources: en.wikipedia.org
No. It is a peptide that acts upstream of growth hormone release, while growth hormone is the hormone itself. The two differ in size, in receptor, and in how the body clears them.
It blocks the amino-terminal degradation step that limits native GHRH. The addition extends how long the peptide survives in plasma without removing its ability to activate the receptor.
The chain contains 44 amino acid residues. It matches the human GHRH(1-44) sequence apart from the amino-terminal modification.
It varies slowly and reflects cumulative axis activity rather than momentary secretion. Growth hormone is released in pulses affected by sleep, stress, and meals, making single readings hard to interpret. The slower marker gives a more stable picture across a study period.